Pancreatic Cancer Research

ResearcherCatharina ZiekenhuisActive in the last 2 years

Geert‐Jan Creemers

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9358-1996; OpenAlex author ID A5113682638. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2015: 2 papers · 2016: 3 papers · 2017: none · 2018: none · 2019: none · 2020: 3 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper

Papers 14

  1. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  2. Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient p… Co-author DOI 10.1080/0284186x.2023.2273898↗
  3. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREO… Co-author DOI 10.1200/jco.21.02233↗
  4. Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. Co-author DOI 10.3389/fonc.2022.839779↗
  5. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. Co-author DOI 10.1016/j.ejso.2020.11.137↗
  6. First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort. Co-author DOI 10.6004/jnccn.2021.7028↗
  7. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. Co-author DOI 10.1016/j.hpb.2019.06.019↗
  8. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. Co-author DOI 10.1080/0284186x.2020.1725241↗
  9. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III P… Co-author DOI 10.1200/jco.19.02274↗
  10. The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis. Co-author DOI 10.1002/cam4.921↗
  11. Developing a core set of patient-reported outcomes in pancreatic cancer: A Delphi survey. Co-author DOI 10.1016/j.ejca.2016.01.001↗
  12. Does long-term survival exist in pancreatic adenocarcinoma? Last author DOI 10.3109/0284186x.2015.1096020↗
  13. The relevance of pathological verification in suspected pancreatic cancer. First author DOI 10.1016/j.canep.2015.01.004↗
  14. Ten weeks to live: a population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. Co-author DOI 10.3109/0284186x.2014.953257↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 10 shared papers, 2016–2023 · strength 0.94
  2. Johanna W. Wilmink · 8 shared papers, 2020–2023 · strength 0.83
  3. Judith de Vos‐Geelen · 8 shared papers, 2020–2023 · strength 0.83
  4. Ignace H. J. T. de Hingh · 10 shared papers, 2015–2022 · strength 0.75
  5. Marjolein Y.V. Homs · 7 shared papers, 2020–2023 · strength 0.75
  6. Hanneke W.M. van Laarhoven · 8 shared papers, 2015–2023 · strength 0.74
  7. Casper H.J. van Eijck · 5 shared papers, 2020–2022 · strength 0.48
  8. Nadia Haj Mohammad · 5 shared papers, 2015–2021 · strength 0.44
  9. Lydia G. van der Geest · 4 shared papers, 2016–2022 · strength 0.41
  10. Bas Groot Koerkamp · 4 shared papers, 2020–2022 · strength 0.38
  11. Izaak Quintus Molenaar · 4 shared papers, 2016–2021 · strength 0.31
  12. Hjalmar C. van Santvoort · 3 shared papers, 2020–2022 · strength 0.28
  13. Gijs A. Patijn · 3 shared papers, 2020–2022 · strength 0.26
  14. Sebastiaan Festen · 3 shared papers, 2020–2022 · strength 0.26
  15. Bert A. Bonsing · 3 shared papers, 2020–2022 · strength 0.26
  16. Esther N. Pijnappel · 2 shared papers, 2021–2022 · strength 0.25
  17. V.E.P.P. Lemmens · 4 shared papers, 2015–2016 · strength 0.24
  18. Geertjan van Tienhoven · 2 shared papers, 2020–2022 · strength 0.18
  19. Jeanin Elise van Hooft · 2 shared papers, 2020–2022 · strength 0.18
  20. Mustafa Suker · 2 shared papers, 2020–2022 · strength 0.18
  21. Eva Versteijne · 2 shared papers, 2020–2022 · strength 0.18
  22. Joost J.M.E. Nuyttens · 2 shared papers, 2020–2022 · strength 0.18
  23. Ferry A.L.M. Eskens · 2 shared papers, 2020–2022 · strength 0.18
  24. Nienke Bernards · 3 shared papers, 2015–2016 · strength 0.18
  25. Tara M. Mackay · 2 shared papers, 2020 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.